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background:  Most patients discharge on sub-maximal statin therapy after acute myocardial infarction (AMI) in Korea because of 
insufficient data regarding the efficacy of high-intensity statin therapy in Asian population. We aimed to assess whether high-intensity statin 
therapy would improve major adverse cardiac events (MACEs) compared with moderate-intensity statin therapy. 
methods:  Between February 2008 and June 2014, 10,243 eligible patients (7,530 men; mean age = 63 ± 12 year-old) were included 
from the Korea AMI Registry. High-intensity statin therapy was defined as either of the followings: 1) use of atorvastatin 40-80mg or 2) 
rosuvastatin 20-40mg. The 6-month MACEs were defined as death, non-fatal MI, and revascularizations. 
Results:  The prescription rate of high-intensity statin therapy was 22.2% (n=2,271). Before propensity score (PS) match, there were no 
significant differences in the 12-month MACEs (5.3% versus 5.3%, p = 0.948) and mortality (2.6% versus 2.7%, p = 0.836) between high-
intensity statin use and moderate-intensity statin use. For each patient, a PS indicating the likelihood of using high-intensity statin use 
during hospitalization or at discharge was calculated using a non-parsimonious multivariable logistic regression model, and was used to 
1:2 match the patients on high-intensity statin therapy with the patients on moderate-intensity statin therapy, leaving 2,144 high-intensity 
statin users versus 4,288 moderate-intensity statin users. The 6-month MACEs and mortality were assessed using matched logistic and 
Cox regression models. Compared with moderate-intensity statin therapy, there was no significant difference in 6-month MACEs between 
high-intensity statin therapy and moderate-intensity statin therapy (5.2% versus 4.5%; hazard ratio [HR] 1.18, 95% confidence interval [CI] 
0.93 - 1.48; p=0.172). 
conclusion:  In real-world practice, high-intensity statin therapy did not improve the 6-month MACEs compared with moderate-intensity 
statin therapy after AMI. Much larger randomized controlled trials are required for Asian population with AMI.
